Back to User profile » Dr Shuji Sato
Papers published by Dr Shuji Sato:
Effects of Pemafibrate on Cardio-Ankle Vascular Index (CAVI) in Patients with Type 2 Diabetes or Ischemic Heart Disease: A 24-Week Observational Study
Watanabe Y, Nonaka S, Yamaoka S, Nakamura S, Horikawa O, Yamaguchi T, Sato S, Todani S, Sugizaki Y, Ito T, Mikamo H, Takahashi M, Nagayama D, Shimizu K, Saiki A
Vascular Health and Risk Management 2025, 21:293-304
Published Date: 24 April 2025
Sacubitril/Valsartan Shows Improvement of the Cardio-Ankle Vascular Index in a Hypertensive Patient
Shimizu K, Tabata T, Iwakawa M, Sato S, Kinoshita T
International Medical Case Reports Journal 2023, 16:461-465
Published Date: 22 August 2023
Rapid Rise in Cardio-Ankle Vascular Index as a Predictor of Impending Cardiovascular Events -Smooth Muscle Cell Contraction Hypothesis for Plaque Rupture -
Shimizu K, Takahashi M, Sato S, Saiki A, Nagayama D, Hitsumoto T, Takahara A, Shirai K
Vascular Health and Risk Management 2022, 18:879-886
Published Date: 19 December 2022
Increased Arterial Stiffness in Chronic Thromboembolic Pulmonary Hypertension Was Improved with Riociguat and Balloon Pulmonary Angioplasty: A Case Report
Sato S, Shimizu K, Ito T, Tsubono M, Ogawa A, Sasaki T, Takahashi M, Noro M, Shirai K
International Medical Case Reports Journal 2021, 14:191-197
Published Date: 29 March 2021
Chronic Thromboembolic Pulmonary Hypertension Due to Popliteal Vein Aneurysm
Tsubono M, Shimizu K, Sato S, Ito T, Ikeda T
International Medical Case Reports Journal 2021, 14:101-106
Published Date: 17 February 2021
Rapid Rise of Cardio-Ankle Vascular Index May Be a Trigger of Cerebro-Cardiovascular Events: Proposal of Smooth Muscle Cell Contraction Theory for Plaque Rupture
Shimizu K, Takahashi M, Sato S, Saiki A, Nagayama D, Harada M, Miyazaki C, Takahara A, Shirai K
Vascular Health and Risk Management 2021, 17:37-47
Published Date: 12 February 2021
The clinical course of symptomatic deep vein thrombosis after 3 months of anticoagulant therapy using fondaparinux/edoxaban or fondaparinux/vitamin K antagonist
Shimizu K, Iiduka T, Sato S, Kiyokawa H, Nakagami T, Mikamo H, Kawazoe M, Takahashi M, Noro M
Therapeutics and Clinical Risk Management 2018, 14:377-383
Published Date: 23 February 2018